RT Journal Article
T1 Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era?
A1 Jiménez Valero, Santiago
A1 Moreno, Raúl
A1 Sanchez Recalde, Ángel
A1 Galeote, Guillermo
A1 Calvo Martín, José Luis
A1 Viana Tejedor, Ana Teresa
A1 Lopez de Sá, Esteban
A1 López Sendón, Jose
AB Restenosis is an important limitation of percutaneous coronary interventions (PCI). In-stent restenosis is mainly due to neointimal hyperplasia, a proliferative process modulated by inflammatory mechanisms. Numerous technical and pharmacological means have been tested to reduce restenosis rates, with frequently disappointing clinical results. Drug-eluting stents (DES) have demonstrated a high efficacy in reducing restenosis, but there are some associated problems that limit its generalized utilization. Glucocorticoids (GC), as potent anti-inflammatory agents, may exert beneficial effects on neointimal proliferation. Clinical studies with oral and intracoronary GC therapy have demonstrated reduction in restenosis rates in selected patients. Although further investigations are warranted, GC might have a potential role for restenosis prevention in selected cases.
PB Sage
SN 1753-9447
SN 1753-9455
YR 2008
FD 2008-06
LK https://hdl.handle.net/20.500.14352/100823
UL https://hdl.handle.net/20.500.14352/100823
LA eng
NO Jimenez-Valero S, Moreno R, Sanchez-Recalde A, et al. Review: Avoiding restenosis: is there a role for glucocorticoids in the drug-eluting stent era? Therapeutic Advances in Cardiovascular Disease. 2008;2(3):137-146. doi:10.1177/1753944708090573
DS Docta Complutense
RD 30 dic 2025